Panel doubts agents' role in improving Alzheimer's diagnosis

01/30/2013 | Reuters

The Medicare Evidence Development & Coverage Advisory Committee showed a lack of confidence in the use of imaging agents to detect brain plaques linked to Alzheimer's disease risk. Only one of the 12 voting members expressed intermediate to high confidence that the agents will help improve outcomes in patients showing early signs of memory problems. This lack of confidence may lead to CMS reimbursement problems for Eli Lilly & Co.'s FDA-approved imaging agent Amyvid. Lilly said it is confident of the usefulness of its product in evaluating patients suspected of having Alzheimer's.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA